Skip Navigation

Phase II, Multicenter, Non-randomized, Open-label, Multi-cohort Study Designed to Evaluate The Efficacy, Safety, And Pharmacokinetics Of Mosunetuzumab SC In Patients With FL, DLBCL, MZL, MCL, RT, or tFL

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05207670

Study #:
STUDY00148821

Start Date:
Oct 13, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05207670

View Complete Trial Details & Eligibility at ClinicalTrials.gov